Get the Stockscreener App
94.20
3.09%
-3.00
Illumina Inc stock is traded at $94.20, with a volume of 3.75M.
It is down -3.09% in the last 24 hours and down -33.34% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$97.20
Open:
$97.91
24h Volume:
3.75M
Relative Volume:
1.65
Market Cap:
$14.92B
Revenue:
$4.39B
Net Income/Loss:
$-1.58B
P/E Ratio:
-9.4578
EPS:
-9.96
Net Cash Flow:
$546.00M
1W Performance:
-6.03%
1M Performance:
-33.34%
6M Performance:
-28.97%
1Y Performance:
-30.94%
1-Day Range:
$93.50
$98.70
1-Week Range:
$93.50
$105.67
52-Week Range:
$93.50
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
94.20 | 14.92B | 4.39B | -1.58B | 546.00M | -9.96 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Roche looks to grow with sequencing by expansion tech - BioWorld Online
Illumina stock touches 52-week low at $94.72 amid market challenges By Investing.com - Investing.com South Africa
Illumina stock touches 52-week low at $94.72 amid market challenges - Investing.com
Constellation technology saves valuable time and unlocks a more complete genome - Illumina
Illumina, Broad Clinical Labs Partner to Expedite Single-Cell Research -February 21, 2025 at 09:59 am EST - Marketscreener.com
Illumina and Broad Clinical Labs enhance single-cell research - Investing.com
Illumina And Broad Clinical Labs Usher In New Era Of Drug Discovery With Collaboration To Rapidly Scale Single-Cell Solutions - Marketscreener.com
Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions – Company AnnouncementFT.com - Financial Times
Circulating Cell-Free Tumor DNA Market Witnessing Substantial - openPR
Ownership Capital B.V. Cuts Stock Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Baillie Gifford & Co. - MarketBeat
Short Interest in Illumina, Inc. (NASDAQ:ILMN) Expands By 9.0% - MarketBeat
China blacklists Illumina, triggers frenzy among rivals to win market share - Medical Buyer
Illumina: New Entrant Roche Aims to Launch Sequencing Platform in 2026 - Morningstar
Illumina's Large Installed System Base Should Insulate It Somewhat From New Entrants - Morningstar
Illumina teases transcriptome profiling tech ahead of 2026 launch - Yahoo Finance
10,958 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by Strategic Financial Concepts LLC - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Buys New Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Principal Financial Group Inc. - MarketBeat
Allworth Financial LP Increases Stock Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina unveils first-of-its-kind spatial transcriptomics technology - BSI bureau
Exome Sequencing Market Is Booming So Rapidly: Illumina, Inc. (USA), Thermo Fisher Scientific, Inc. (USA) - openPR
Chinese Rivals Seize on Illumina’s Blacklisting to Woo Clients - Bloomberg
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Rhumbline Advisers - MarketBeat
Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference - Eastern Progress
Cathie Wood Explains AI Growth Catalysts for Illumina (ILMN) - Insider Monkey
Why Illumina Inc. (ILMN) Went Down on Monday - MSN
TD Cowen holds Illumina stock with $140 target By Investing.com - Investing.com UK
Illumina Unveils Spatial Technology Days Before AGBT Meeting - Genetic Engineering & Biotechnology News
Illumina (NASDAQ:ILMN) Reaches New 1-Year LowHere's What Happened - MarketBeat
The Dawn of Genetic Mastery? Meet Illumina’s New Frontier. - Jomfruland.net
BofA Securities Cuts Price Target on Illumina to $90 From $110, Keeps Underperform Rating - Marketscreener.com
Biomarker Research Services Market Set to Witness Significant Growth by 2025-2032:Siemens Healthineers AG, - EIN News
Van ECK Associates Corp Purchases 22,718 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
DNA Test Kits Market Future Business Opportunities 2025-2032 | - openPR
Microfluidic Market Growth in Future Scope 2025-2032 | Agilent Technologies, Inc., Illumina, Inc., Perkinelmer, Inc. - openPR
Chevy Chase Trust Holdings LLC Boosts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Illumina's SWOT analysis: stock outlook amid sequencing market shifts - MSN
Illumina’s SWOT analysis: stock outlook amid sequencing market shifts By Investing.com - Investing.com Nigeria
Single Cell Genome Sequencing Market to Witness Rapid Expansion - openPR
Life Science Tools Market Is Booming Worldwide 2025-2032: Hitachi, Ltd., Illumina, Inc., Oxford Instruments, - EIN News
New York State Teachers Retirement System Sells 2,900 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Asset Management One Co. Ltd. Increases Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina Inc.: Is its Transition to NovaSeq X Series Noteworthy? - Smartkarma
Brokerages Set Illumina, Inc. (NASDAQ:ILMN) Price Target at $159.45 - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Makes New $448,000 Investment in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina partners with Nvidia on AI-powered genomic sequencing - MSN
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Louisiana State Employees Retirement System - MarketBeat
Banque Pictet & Cie SA Trims Stake in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina (NASDAQ:ILMN) Stock Rating Lowered by Barclays - MarketBeat
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
3.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):